Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23887Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Pentheroudakis, G. | en |
| dc.contributor.author | Malamou-Mitsi, V. | en |
| dc.contributor.author | Briasoulis, E. | en |
| dc.contributor.author | Damala, K. | en |
| dc.contributor.author | Vassou, A. | en |
| dc.contributor.author | Vartholomatos, G. | en |
| dc.contributor.author | Kolaitis, N. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:36:29Z | - |
| dc.date.available | 2015-11-24T19:36:29Z | - |
| dc.identifier.issn | 0008-543X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23887 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adenocarcinoma/blood/drug therapy/pathology | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Bone Marrow/pathology | en |
| dc.subject | Breast Neoplasms/blood/*drug therapy/pathology | en |
| dc.subject | Carcinoma, Ductal/blood/drug therapy/pathology | en |
| dc.subject | Chemotherapy, Adjuvant | en |
| dc.subject | Female | en |
| dc.subject | Flow Cytometry | en |
| dc.subject | Granulocyte Colony-Stimulating Factor/*therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Mucin-1/*metabolism | en |
| dc.subject | Neoplasm Invasiveness/pathology | en |
| dc.subject | Neutrophils/*metabolism | en |
| dc.subject | Prospective Studies | en |
| dc.subject | Tumor Markers, Biological/*analysis | en |
| dc.title | The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1002/cncr.20581 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/15386335 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1002/cncr.20581/asset/20581_ftp.pdf?v=1&t=h0t6994e&s=499596cd3c7983ad3f52f9d63388b1192152daec | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2004 | - |
| heal.abstract | BACKGROUND: Patients with resected breast carcinoma who received granulocyte-colony-stimulating factor (G-CSF)-supported adjuvant chemotherapy exhibited an increase in their serum CA 15-3 levels. The authors investigated the role of G-CSF-induced neutrophil MUC1 expression in this setting. METHODS: Twenty-two patients with resected early breast carcinoma and 6 patients with high-grade lymphoma received chemotherapy cycles with or without G-CSF support. When given, G-CSF was administered for either 5 or 10 days per cycle. Immunocytochemical staining and flow cytometric analysis of peripheral blood neutrophils and bone marrow myeloid cells for MUC1 epitopes were performed during treatment. RESULTS: At baseline, the median serum CA 15-3 was 16 U/mL, with weak MUC1 expression in peripheral neutrophils (median immunocytochemical score [ICCS] = 40, flow cytometric score [FCS] = 211 antibody molecules per neutrophil). For patients receiving chemotherapy cycles with 5-day G-CSF support, median CA 15-3 levels increased moderately (median = 28 U/mL; P = 0.016) and absolute neutrophil counts (ANC) did not increase, whereas ICC staining showed a moderate increase (median ICCS = 105; P = 0.015). For patients receiving chemotherapy cycles with 10-day G-CSF, serum CA 15-3 levels increased 2-4-fold from baseline levels and reached abnormal levels (median = 47; P < 0.0005) and the ANC increased (median = 21,400/mm(3); P = 0.007), whereas significant induction of MUC1 expression occurred in the cell membrane and mostly in the cytoplasm of neutrophils (median ICCS = 162; P = 0.001). Flow cytometry detected increased cytoplasmic, but not surface, neutrophil MUC1 expression in the 10-day G-CSF group only (baseline median FCS = 3975, 4th cycle median = 6327 molecules per cell; P = 0.028). In the bone marrow, induction of MUC1 expression was observed in the 10-day G-CSF group only in band forms and neutrophils, but not in more immature myeloid cells. Serum CA 15-3 levels and ICC score were found to demonstrate a linear relation. When ICCS and ANC were incorporated in a combined score, its relation with serum CA 15-3 levels demonstrated a parabolic (cubic) pattern. Serum CA 15-3 levels, ANC, and neutrophil MUC1 staining returned to baseline after the completion of therapy. No excess of malignant recurrences were observed. CONCLUSIONS: Women with resected breast carcinoma who received G-CSF-primed chemotherapy showed serum CA 15-3 elevation due to an increase in peripheral blood neutrophil number and induced neutrophil cytoplasmic MUC1 expression, which was caused by G-CSF. Physicians should be aware of this interaction. | en |
| heal.journalName | Cancer | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Pentheroudakis-2004-The neutrophil, not.pdf | 140.78 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
